Home Newsfeeds Dawson James Upgrades Arcimoto to Neutral

Dawson James Upgrades Arcimoto to Neutral

Dawson James analyst James McIlree upgrades Arcimoto (NASDAQ:FUV) from Sell to Neutral.

byBenzinga Newsdesk

February 15, 2023

1 minute read

Dawson James analyst James McIlree upgrades Arcimoto (NASDAQ:FUV) from Sell to Neutral.

HSBC Upgrades Essential Utilities to Buy, Raises Price Target to $57

By Benzinga Newsdesk

August 18, 6:22 AM

HSBC analyst Verity Mitchell upgrades Essential Utilities (NYSE:WTRG) from Hold to Buy and raises the price target from $53 to $57.

WTRG

Events
News

Gilead’s Kites Announced Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Yescarta CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma at ASH 2022

By Charles Gross

December 11, 9:13 PM

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta® (axicabtagene ciloleucel), the largest and longest follow-up of a CAR T-cell therapy versus standard of care (SOC) in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL).

GILD